Cargando…
An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation
Aberrant CXCR4/CXCL12 signaling is involved in many pathophysiological processes such as cancer and inflammatory diseases. A natural fragment of serum albumin, named EPI-X4, has previously been identified as endogenous peptide antagonist and inverse agonist of CXCR4 and is a promising compound for t...
Autores principales: | Harms, Mirja, Habib, Monica M.W., Nemska, Simona, Nicolò, Antonella, Gilg, Andrea, Preising, Nico, Sokkar, Pandian, Carmignani, Sara, Raasholm, Martina, Weidinger, Gilbert, Kizilsavas, Gönül, Wagner, Manfred, Ständker, Ludger, Abadi, Ashraf H., Jumaa, Hassan, Kirchhoff, Frank, Frossard, Nelly, Sanchez-Garcia, Elsa, Münch, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463264/ https://www.ncbi.nlm.nih.gov/pubmed/34589390 http://dx.doi.org/10.1016/j.apsb.2020.12.005 |
Ejemplares similares
-
Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists
por: Sokkar, Pandian, et al.
Publicado: (2021) -
Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands
por: Harms, Mirja, et al.
Publicado: (2020) -
Development
of N-Terminally Modified Variants
of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability
por: Harms, Mirja, et al.
Publicado: (2023) -
Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations
por: Gilg, Andrea, et al.
Publicado: (2021) -
Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability
por: Rodríguez-Alfonso, Armando, et al.
Publicado: (2022)